Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
38.10
+0.09 (0.24%)
At close: Jun 26, 2026, 4:00 PM EDT
38.39
+0.29 (0.76%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Cogent Biosciences Employees
Cogent Biosciences had 258 employees as of December 31, 2025. The number of employees increased by 53 or 25.85% compared to the previous year.
Employees
258
Change (1Y)
53
Growth (1Y)
25.85%
Revenue / Employee
n/a
Profits / Employee
-$1,373,267
Market Cap
6.51B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| CG Oncology | 142 |
| Spyre Therapeutics | 112 |
| Definium Therapeutics | 106 |
COGT News
- 15 days ago - Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress - GlobeNewsWire
- 15 days ago - Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - GlobeNewsWire
- 18 days ago - Cogent Biosciences Transcript: AGM 2026 - Transcripts
- 24 days ago - Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 27 days ago - Cogent Biosciences announces data from analysis of PEAK Phase 3 trial - TheFly
- 4 weeks ago - Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Cogent Biosciences announces FDA acceptance of bezuclastinib NDA - TheFly
- 4 weeks ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST - GlobeNewsWire